EUVIMEDOpdag EUVIMED
Crossref

Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy

Kimberly Pasley, Mariah Eisner, Stephanie Sliemers, Rylie Young, Mary Lynn Dell, Karen S McCoy, Anne May

Pediatric Pulmonology · 2025

DOI: 10.1002/ppul.27393 ↗

At a glance

Journal article in Pediatric Pulmonology, 2025. Written by Kimberly Pasley and 6 co-authors. Institution: Division of Pulmonary and Sleep Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA. Major MEDLINE topics: Cystic Fibrosis, Aminophenols, Quinolones, Benzodioxoles. Cited 9 times so far (Crossref); 25 references. Funded by: The Clinical and Translational Intramural Funding Program through the Abigail Wexner Research Institute at Nationwide Children's Hospital.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Research studies are conflicting regarding new highly effective modulators and the association with mental health symptoms for adults and adolescents with cystic fibrosis (CF). For younger children, small studies and case reports indicate a wide range of effects, ranging from improvement in mood to the development of neuropsychiatric symptoms. However, a large placebo‐controlled study indicated no causal connection. This study evaluates the frequency and severity of mental health symptoms in children and adolescents while taking elexacaftor/tezacaftor/ivacaftor (ETI).

Methods

The study includes 81 pediatric patients with CF followed at Nationwide Children's Hospital (NCH). Patient Reported Outcomes Measurement Information System (PROMIS)‐Anxiety and Depression, Patient Health Questionnaire 8 (PHQ‐8) and Generalized Anxiety Disorder Questionnaire (GAD‐7) were used to screen for depression and anxiety. Age‐appropriate questionnaires were completed over the first 18 months after initiating ETI.

Results

At baseline, majority of participants reported mental health symptoms within normal limits (WNL). For participants with elevated baseline measures, depressive and anxiety symptoms significantly decreased throughout the study period. Depending on the metric, patients experiencing depressive and anxiety symptoms dropped to 2−3% ( n = 1, on each depressive measure) and 0% ( n = 0, on either anxiety measures) respectively by 18 months.

Conclusion

Most pediatric patients with CF did not endorse symptoms of depression or anxiety disorders at ETI initiation. Over the first 18 months of ETI usage, the percentage of patients with these symptoms decreased, suggesting that the percentage of patients experiencing severe symptoms of depression and anxiety may decrease with ongoing use of ETI.

Subjects

MeSH terms (MEDLINE)

Cystic FibrosisAminophenolsQuinolonesBenzodioxolesIndolesPyrazolesDepressionPyrrolidinesPyridinesHumansMaleFemaleAdolescentChildDrug CombinationsAnxietyMental HealthPatient Reported Outcome MeasuresSurveys and QuestionnairesQuinolines

Author keywords

ADHDcystic fibrosiselexacaftor‐tezacaftor‐ivacaftormental health

Substances

AminophenolsQuinolonesBenzodioxolesDrug CombinationsIndolesPyrazolesPyrrolidinesPyridineselexacaftor, ivacaftor, tezacaftor drug combinationtezacaftor, ivacaftor drug combination

Authors and institutions

  • Division of Pulmonary and Sleep Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Biostatistics Resource, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Department of Psychiatry, Institute of Living, Hartford, Connecticut, USA.
  • Department of Psychiatry, University of Connecticut, Hartford, Connecticut, USA.

Funding

  • The Clinical and Translational Intramural Funding Program through the Abigail Wexner Research Institute at Nationwide Children's Hospital

Cite

APA

Pasley, K., Eisner, M., Sliemers, S., Young, R., Dell, M. L., McCoy, K. S., & May, A. (2025). Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27393

Vancouver

Pasley K, Eisner M, Sliemers S, Young R, Dell ML, McCoy KS, et al. Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy. Pediatric Pulmonology. 2025. doi:10.1002/ppul.27393

BibTeX
@article{Pasley2025,
  author = {Pasley, Kimberly and Eisner, Mariah and Sliemers, Stephanie and Young, Rylie and Dell, Mary Lynn and McCoy, Karen S and May, Anne},
  title = {Mental Health of Pediatric Patients with Cystic Fibrosis after 18 Months on Elexacaftor‐Tezacaftor‐Ivacaftor Therapy},
  journal = {Pediatric Pulmonology},
  year = {2025},
  doi = {10.1002/ppul.27393}
}
Start for free →